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Background: Aging and aging-related disorders impair the survival and differentiation 
potential of bone marrow mesenchymal stem cells(BM-MSCs) and limit their 
therapeutic efficacy. Induced pluripotent stem cells(iPSCs) may provide an alternative 
source of functional MSCs for tissue repair. This study aimed to generate and 
characterize human iPSC-derived MSC and to investigate their biological function for 
the treatment of limb ischemia.  
Methods and Results: Human iPSCs were induced to MSC differentiation using a 
clinically compliant protocol. Three monoclonal, karyotypically stable and functional 
MSC-like cultures were successfully isolated using a combination of CD24- and 
CD105+ sorting. They did not express pluripotent-associated markers, but displayed 
MSC surface antigens and differentiated into adipocytes, osteocytes and 
chondrocytes. Transplanting iPSC-MSCs into mice significantly attenuated severe 
hind-limb ischemia and promoted vascular and muscle regeneration. The benefits of 
iPSC-MSCs on limb ischemia were superior to those of adult BM-MSCs.  The greater 
potential of iPSC-MSCs may be attributable to their superior survival and engraftment 
following transplantation to induce vascular and muscle regeneration via direct de-
novo differentiation and paracrine mechanisms. 
Conclusion: Functional MSCs can be clonally generated, beginning at a single cell 
level, from human iPSCs. Compared to adult bone marrow derived MSCs, 
transplanting iPSC-MSCs into mice achieved a better beneficial effect in attenuation 
of severe limb ischemia.  Our study provides a proof-of-concept that functional MSCs 
can be generated from human iPSC and used to treat ischemic disease in a patient-
specific, cost-effective and batch-to-batch consistent manner.   
 
